Research programme: cysteine endopeptidase inhibitors - Amura

Drug Profile

Research programme: cysteine endopeptidase inhibitors - Amura

Alternative Names: AM-3701; AM-3840; AM-3876

Latest Information Update: 27 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amura
  • Class Small molecules
  • Mechanism of Action Cathepsin K inhibitors; Cathepsin S inhibitors; Cysteine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bone metastases; Malaria; Neuropathic pain; Osteoarthritis; Osteoporosis; Rheumatoid arthritis

Most Recent Events

  • 27 Jul 2016 Preclinical development is ongoing for Osteoporosis, Bone metastases, Osteoarthritis, Rheumatoid arthritis, Neuropathic pain and Malaria in United Kingdom (Amcure website, July 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bone metastases in United Kingdom
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Malaria in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top